EDAP TMS S.A. (EDAP) has a MoatMap StockRank of 50/100 based on Quality (25/100), Value (38/100), and Momentum (73/100) factor scores. The current signal is HOLD. EDAP TMS is a small medical device company specializing in therapeutic ultrasound. While its technology is promising, it is pre-scale, has inconsistent profitability, and lacks the robust financial quality metrics (high ROIC, consistent FCF) required by our Buffett and Smith lenses.
EDAP TMS S.A. is a French medical device company that designs, manufactures, and markets minimally invasive therapeutic ultrasound equipment, primarily for the treatment of prostate cancer. The company's competitive moat is established by its proprietary High-Intensity Focused Ultrasound (HIFU) technology, commercialized through its flagship Focal One device. EDAP is a global leader in non-invasive urological therapies, benefiting from expanding regulatory approvals and growing clinical adoption worldwide.
| Price | $4.66 |
| Market Cap | $157M |
| P/E (Forward) | -7.32 |
| Price/Book | 8.34 |
| Return on Equity | -124.0% |
| Return on Invested Capital | -66.9% |
| Debt/Equity | 275.14 |
| Gross Margin | 43.4% |
| Operating Margin | -41.4% |
| Revenue Growth | 13.9% |
| Free Cash Flow | $-10M |
EDAP TMS S.A. operates in the Medical Distribution industry, part of the Healthcare sector (France).